You are viewing the site in preview mode
Skip to main content
|
Characteristic
|
Healthy control (HC)
|
Ulcerative colitis (UC)
|
Crohn’s disease (CD)
|
|---|
|
n
|
17
|
11
|
7
|
|
Male/female
|
7/10
|
4/7
|
2/5
|
|
Age at sampling
|
44.3 (17-86)
|
46 (26-65)
|
58.6 (23-80)
|
|
Inflammation categories
|
|
CRP (> 5)
| |
3
|
1
|
|
ESR (> 20)
| |
1
|
0
|
|
Faecal calprotectin (> 55)
| |
2
|
1
|
|
Symptoms at sampling
| | | |
|
Diverticular disease
| |
1
|
0
|
|
Diversion colitis
| |
0
|
1
|
|
Fistulating Crohn’s
| |
0
|
1
|
|
IBD medications at sampling
|
|
None
| |
9
|
5
|
|
Aminosalicylates
| |
2
|
1
|
|
Azathioprine/6-mercaptopurine
| |
0
|
0
|
|
Adalimumab
| |
0
|
1
|
|
Non-IBD medications at sampling
|
|
Vitamins D/D3/ B12/B9
| |
1
|
1
|
|
Loperamide
| |
0
|
1
|
|
Alendronate
| |
0
|
1
|
|
Metformin
| |
1
|
0
|
|
Tamoxifen
| |
1
|
0
|
|
Simvastatin
| |
1
|
0
|
|
None
| |
10
|
6
|
- Demographic and clinical data analysed in Figs. 1, 2, 3, 4 and 5 and Supplementary Fig 1-4
